RASGRP2

Across TCGA pan-cancer cohorts, RASGRP2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of RASGRP2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where RASGRP2 RNA is repressed in tumor relative to normal tissue. In most cancer types RASGRP2 is over-expressed in tumor, although a few such as BLCA and KICH show the opposite, repressed pattern.

BLCA, KICH, and LUAD are the cancer types where RASGRP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RASGRP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−3.222	<.001	12	view →
KICH	All	III,IV	−1.847	<.001	11	view →
LUAD	Male	III,IV	−1.493	<.001	9	view →
COAD	Male	II,III,IV	−1.053	<.001	9	view →
KIRP	Male	All	−0.915	<.001	9	view →
LUSC	Female	All	−2.182	<.001	8	view →
KIRC	Female	All	+0.763	<.001	8	view →
UCEC	All	III,IV	−2.338	<.001	6	view →
BRCA	All	II,III,IV	−0.843	<.001	6	view →
THCA	All	All	−0.535	.013	4	view →
READ	All	All	−1.103	.019	2	view →
PRAD	All	All	−0.704	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

RASGRP2–BLCA

Open the BLCA breakdown →